Latest News
American Airlines Fuel Costs Surge as Merger Prospects Fade
American Airlines stock fell 5.9% last week as fuel costs surge and United merger talks stall. Brent crude hit $97.15, with American warning of $4B+ fuel expense hike.
Delta Returns to Hong Kong with Daily LAX Flights, Challenging United and Cathay
Delta Air Lines relaunched daily Los Angeles-Hong Kong flights, directly challenging United and Cathay Pacific amid high fuel costs and tough competition.
Battalion Oil Surges Premarket as Crude Soars on Middle East Tensions
Battalion Oil surged as much as 48.5% premarket Monday as crude oil jumped over 4% on Middle East supply fears, putting the small-cap producer back on trader screens.
Air Liquide Shares Dip 10% After Bonus Share Adjustment
Air Liquide shares dropped 0.90% to €165.22 after a 1-for-10 bonus-share adjustment, a technical move unrelated to fundamentals. Investors await the June 9 meeting and July 28 H1 results.
Asia Tech Rout: KOSPI Circuit Breaker Triggered as AI Stocks Tumble
South Korea's KOSPI fell 8.3%, triggering circuit breakers, as AI chip stocks plunged on rising oil prices and Fed rate hike expectations, exposing Asia's reliance on tech giants.
Keel Infrastructure Shares Rebound After $400M AI Data Center Debt Deal
Keel Infrastructure shares gained 3.1% in pre-market trading after pricing a $400M convertible note deal for AI data center expansion, recovering from Friday's 13.5% decline due to dilution fears.
Intesa Sanpaolo's €30.6B Bid Drives MPS Shares Up 10.9%
MPS shares jumped 10.9% to €9.921 after Intesa Sanpaolo's €30.6B cash-and-share bid, offering a 12.5% premium and triggering takeover rules.
Hyperscale Data's $0.21 Buyback Offer Nears Expiration After 25% Friday Drop
Hyperscale Data's $0.21/share buyback, 39% above Friday's close, expires Monday night. The offer covers up to 5.1% of shares.
Zealand Pharma Stock Plunges 26% on High Dropout Rate for Obesity Drug
Zealand Pharma shares fell 26% as investors focused on a 19% dropout rate for survodutide, far exceeding the 2.9% for placebo, despite promising fat-loss data.